PLIAGLIS (lidocaine and tetracaine) by Crescita Therapeutics is amide-type local anesthetic agent and tetracaine is an ester-type local anesthetic agent. First approved in 2006.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
PLIAGLIS is a topical cream combining lidocaine (amide) and tetracaine (ester) local anesthetics that block sodium ion channels to provide dermal analgesia. Applied directly to intact skin via a peel-off formulation, it delivers rapid localized pain relief without systemic absorption. The dual-agent approach enhances onset and duration of anesthesia for dermatological and minor surgical procedures.
Product is in peak commercial phase with mature market presence; team size likely stable to modest, focusing on market maintenance rather than expansion.
amide-type local anesthetic agent and tetracaine is an ester-type local anesthetic agent. Both lidocaine and tetracaine block sodium ion channels required for the initiation and conduction of neuronal impulses which, in certain instances, results in local anesthesia. When applied to intact skin,…
Amide Local Anesthetic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Non-interventional Study to Evaluate the Use of Pliaglis in Daily Practice
Evaluate Efficacy, Safety & Subject Satisfaction of Pain Management With Pliaglis® Cream for Dermal Filler Injections
Worked on PLIAGLIS at Crescita Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~5 years — strategic planning for patent cliff underway
Working on PLIAGLIS offers stable, predictable commercial responsibilities in a mature therapeutic with established market presence and clear competitive dynamics. Career progression emphasizes sales execution, market maintenance, and account management rather than innovation or launch-phase excitement.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo